Trade Mark Journal No.2025/022 30 May 2025

WO0000001853792 (5)

Office of origin: United States of America

Date of International Registration:2 April 2025
Date of designation in the UK: 2 April 2025
Image for mark 1853792 RDRUG

International priority date claimed: 10 October 2024 (United States of America) (98794435)
Class 5
Small molecule pharmaceutical preparations for use in cell and gene therapy for treating respiratory and infectious diseases and metabolic disorders, and diseases and disorders of the neurological, oncology, cardiovascular, immune, endocrine, gastrointestinal, ophthalmic, dermatologic and hematologic systems.

Rgenta Therapeutics, Inc.

Representative: Jessica L. Rothstein GOODWIN PROCTER LLP, 620 Eighth Avenue, New York NY 10018, UNITED STATES OF AMERICA